A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Grants and Contracts Details

StatusActive
Effective start/end date8/20/19 → 2/6/25

Funding

  • Eisai Incorporated: $1,042,220.00